Analytical method validation. Presented by Debbie Parker 4 July, 2016

Similar documents
STABILITY INDICATING ASSAY. differentiate an intact drug from its potential decomposition products 425.

Method Development and Validation for Nutraceuticals

Sanjog Ramdharane 1, Dr. Vinay Gaitonde 2

CHAPTER 2 SIMULTANEOUS DETRMINATION OF ANASTROZOLE AND TEMOZOLOMIDE TEMOZOLOMIDE CAPSULES 20 MG AND ANASTROZOLE TABLETS 1 MG

Residual Solvents: FDA/ Regulatory Perspective

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

Topics covered by the talk

Journal of Chemical and Pharmaceutical Research

Development and validation of liquid chromatographic method for trazodone hydrochloride

Cross Contamination & the EU GMP Guide. Bryan J Wright July 2017

HPTLC Determination of Atomoxetine Hydrochloride from its Bulk Drug and Pharmaceutical Preparations

Organic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

General concepts in the Ph. Eur.: theory and rationale

Available online at Scholars Research Library

US FDA Process Validation Guidance. Presented by Marc Fini 21 May, 2013

Measuring Lipid Composition LC-MS/MS

USP <232> and <233> Understanding Your Path to Compliance with the New Elemental Impurity Chapters. Steve Wall Agilent Technologies

Overview Internal review

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

F. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations

Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets

New Annex 15 Updated Requirements & Approach to Validation. Presented by Ashley Isbel 10 th August 2015

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Development and Validation of a RPLC Method for the Determination of 2-Phenoxyethanol in Senselle Lubricant Formulation

Continuous & Continued Process Verification. Presented by Eoin Hanley 4 July, 2016

CONTENT. i iv ix. SVKM s NMIMS, School of Pharmacy and Technology Management

Available online Research Article

Analytical method validation for tablet of phenoxymethyl penicillin potassium by RP-HPLC method

Annex 5. Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories

Scholars Research Library. Der Pharmacia Lettre, 2015, 7 (5):44-49 (

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

2. Review of literature: 2.1 General review on methods of simultaneous determination of hypertensive drugs.

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

QUALITY OF HERBAL REMEDIES

Formulation stability studies. 9.1 OBJECTIVE To monitor the stability of the developed herbal formulations using the limited and specific methods.

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS

KEYWORDS: Forced degradation fusidic acid HPLC Method validation Topical formulation.

A Validated Stability Indicating RP-HPLC Method for Simultaneous Estimation of Valsartan and Clinidipine Combined Tablet dosage forms

International Journal of Pharmaceutical Research & Analysis

EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines

Reference Standards in the Analysis of Botanicals

Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

A New USP Tool The Class Monograph

Pankti M. Shah et al, Asian Journal of Pharmaceutical Technology & Innovation, 04 (17); 2016; 07-16

MEDAK DIST. ANDHRA PRADESH STATE, INDIA. Research Article RECEIVED ON ACCEPTED ON

SUMMARY, CONCLUSION & RECOMMENDATIONS

Setting up deviation, incident, nonconformance. Presented by Debbie Parker 4 July, 2016

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

Journal of Chemical and Pharmaceutical Research

Dhull Rohit, Kumar Sanjay, Jalwal Pawan Department of Chemistry, OPJS Churu, Rajasthan, India

Analysis of Common Sweeteners and Additives in Beverages with the PerkinElmer Flexar FX-15 System Equipped with a PDA Detector

Overview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017

Journal of Chemical and Pharmaceutical Research, 2013, 5(1): Research Article

ANALYTICAL TECHNIQUES FOR THE QUALITY OF ANTI- AIDS DRUGS

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF TRAMADOL IN PURE AND PHARMACEUTICAL FORMULATIONS

Research Article Derivative Spectrophotometric Method for Estimation of Metformin Hydrochloride in Bulk Drug and Dosage Form

GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

International Journal of Pharma and Bio Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF STRONTIUM RANELATE IN SACHET

NOVEL RP-HPLC METHOD. B.Lakshmi et a. concentration range KEY INTRODUCTION. Diltiazem is used to. . It works by of contractionn of the. (dilate).

International Journal of Pharma and Bio Sciences

Volume 2 (6), 2014, Page CODEN (USA)-IJPRUR, e-issn: International Journal of Pharma Research and Health Sciences

J Pharm Sci Bioscientific Res (4): ISSN NO

AD HOC WORKING GROUP ON HERBAL MEDICINAL PRODUCTS

Research Article Simultaneous Estimation of DL-Methionine and Pyridoxine Hydrochloride in Tablet Dosage Form by RP-HPLC

Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation

Stability Study of Hydralazine HCl Oral Solutions Compounded in Humco Oral Vehicles to Determine a Beyond-use Date

Vol. 41(1) [Jan. Feb. 2015] (P) \\uspnetapp2\share\share\uspnf\printq\pager\xmlin\lyc_ _m99989.xml. Nov.

PHARMACEUTICAL STABILITY OF PROMETHAZINE IN IV INFUSION FLUIDS Brittenham K, Choi R, Kapraly M, Kime B, Knoebel J

S. G. Talele, D. V. Derle. Department of Pharmaceutics, N.D.M.V.P. College of Pharmacy, Nashik, Maharashtra, India

Simultaneous estimation of Metformin HCl and Sitagliptin in drug substance and drug products by RP-HPLC method

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

Method Validation for Simultaneous Estimation of Prednisolone and Abiraterone Acetate by RP-HPLC

CORESTA RECOMMENDED METHOD NÄ 9

METHOD VALIDATION: WHY, HOW AND WHEN?

Technical Monograph n 17, 2nd Edition. Guidelines for Specifying the Shelf Life of Plant Protection Products

Cleaning validation. Presented by Marc Fini 21 May, 2013

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

(KCCM10741P) (FAD ; CRL/170023)

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

This document is a preview generated by EVS

Impurity Profiling of Carbamazepine by HPLC/UV

OLIN CORPORATION SALES SPECIFICATION

USP Perspective on Atypical Actives November 29, 2017

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

Development and validation of related substances method for Varenicline and its impurities

A Validated RP-HPLC Method for the Determination of Recombinant Human Insulin in Bulk and Pharmaceutical Dosage Form

ISO IDF 177 INTERNATIONAL STANDARD. Dried skimmed milk Determination of vitamin D content using high-performance liquid chromatography

Decentralised Procedure. Public Assessment Report. Zolmitriptan Renantos 2.5 mg Orodispersible film 5 mg Orodispersible film DE/H/2295/ /DC

Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products

Thank you for your requests under the Freedom of Information Act Please find below responses to your questions.

DETERMINATION OF COMPOSITION OF TRIACYLGLYCEROLS AND COMPOSITION AND CONTENT OF DI-ACYLGLYCEROLS BY CAPILLARY GAS CHROMATOGRAPHY, IN VEGETABLE OILS

ISO IDF 176 INTERNATIONAL STANDARD. Milk and milk products Microbial coagulants Determination of total milkclotting

DEVELOPMENT AND VALIDATION OF AN UV- SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF FLUOXETINE IN PURE AND TABLET DOSAGE FORMS

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

Development and Validation of a UV-Spectrophotometric Method for Quantification of Atorvastatin in Tablets

Transcription:

Analytical method validation Presented by Debbie Parker 4 July, 2016

Introduction This session will cover: Guidance and references The types of test methods Validation requirements Summary Slide 2 PharmOut 2015

References ICH Q2(R1) Validation of Analytical procedures: Text and Methodology FDA Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics July 2015 FDA Guidance for Industry - Q2B Validation of Analytical Procedures: Methodology FDA CDER reviewer guideline for validation of chromatographic methods (1994) WHO TRS 937 Appendix 4 Analytical Method Validation 2006 ICH Q2(R1) 2005 Compendia General Chapters Slide 3 PharmOut 2015

Recent changes FDA has just released a new guidance document: Analytical Procedures and Methods Validation for Drugs and Biologics, Guidance for Industry, July 2015 Supersedes the draft document (same name) published Feb 2014 Replaces: Analytical Procedures and Methods Validation, 2000 Slide 4 PharmOut 2015

New guidance Method content Principle/ Scope Apparatus/Equipment Operating parameters Reagents/Standards Sample preparation Standards/Control Solution preparation Procedure System Suitability Calculations Data reporting Slide 5 PharmOut 2015

New Guidance - Reagents / Standards Grade of chemical (e.g., USP/NF, American Chemical Society, High 157 Performance or Pressure Liquid Chromatography, or Gas 158 Chromatography and preservative-free) Source (e.g., USP reference standard, qualified in-house reference material, 160 WHO International Standard/Reference Material, CBER standard) Purity (for pure chemicals only), State (e.g., dried, undried), and concentration Potencies (where required by CFR, USP) Storage conditions Directions for safe use (as per current Safety Data Sheet) Validated or documented shelf life Slide 6 PharmOut 2015

Goal The aim of validating an analytical procedure is to demonstrate that it is fit for purpose. Slide 7 PharmOut 2015

Types of methods ICH splits into four : Identification tests Impurities - Quantitative (content of) Impurities - Limit (control of) Quantitative tests (API or component(s) in drug substance / product) Slide 8 PharmOut 2015

Validation requirements for analytical assays: ICH Q2(R1) Slide 10 PharmOut 2015

Validation requirements for analytical assays: ICH Q2(R1) Slide 11 PharmOut 2015

Methods to be validated - Identification Identification tests: identify the analyte compare test sample to a standard E.g. Spectrum, chemical reactivity, chromatograph etc. Slide 12 PharmOut 2015

Methods to be validated - Impurities Impurities: ensure impurities are as low as required quantitative test or limit test accurate reflection of the purity characteristics validation requirements differ between the two impurity tests Slide 13 PharmOut 2015

Methods to be validated - assays Assay: Quantitatively measure the major component(s) in the drug product Validation requirements similar for: Active ingredients Other selected component(s) Other analytical procedures (e.g. dissolution) Slide 14 PharmOut 2015

Validation tests The objective of the analytical procedure must be understood to determine which of the validation characteristics will be evaluated. Consider the following characteristics: Accuracy Precision Repeatability Intermediate precision Specificity Detection Limit Quantitation Limit Linearity Range Slide 15 PharmOut 2015

Accuracy closeness of the value obtained to the reference ( true ) value determined across the range of the analytical procedure Slide 16 PharmOut 2015

Accuracy There are several methods to determine accuracy. Examples: Apply the procedure to an analyte of known purity (reference) Apply the procedure to synthetic mixtures of the drug product components to which known quantities of the drug substance to be analysed have been added Slide 17 PharmOut 2015

Precision The precision of a procedure is the closeness of a series of measurements from different sampling of the same homogenous sample. If a homogenous sample cannot be obtained, use artificially prepared samples or a sample solution. Slide 18 PharmOut 2015

Accurate and precise Slide 19 PharmOut 2015

Precision There are three levels of precision: Repeatability Intermediate precision Reproducibility Slide 20 PharmOut 2015

Repeatability Repeatability uses the same operating conditions over a short interval of time, also called intra-assay precision. Same laboratory One analyst Same day Same equipment Slide 21 PharmOut 2015

Repeatability Repeatability should be assessed using either: A minimum of 9 determinations covering the specified range (e.g. 3 concentrations/3 replicates) A minimum of 6 determinations at 100% of the test concentration Slide 22 PharmOut 2015

Intermediate precision Intermediate precision assesses the variation within laboratories: Same laboratory Multiple days Multiple analysts Different equipment Slide 23 PharmOut 2015

Reproducibility assesses the precision between laboratories; it is an interlaboratory trial should be considered when standardising methodology e.g. for inclusion in pharmacopoeias or collaborative studies Slide 24 PharmOut 2015

Specificity Specificity should be investigated for the validation of: Identification tests Ensure the identity of an analyte Purity tests Demonstrate accurate content of impurities of an analyte Assay (content or potency) Provide accurate content or potency of the analyte in a given sample Slide 25 PharmOut 2015

Specificity Identity, impurities and assay tests ability to detect the analyte in a sample in the presence of other components which may also be present. may not always be able to demonstrate that an analytical procedure is specific for a particular analyte (complete discrimination). Use two or more procedures to achieve the required discrimination. Slide 26 PharmOut 2015

Specificity Identification test Should be able to discriminate between compounds of related structures which may be present. Use scientific judgement to choose potential interfering materials. Typically would confirm discrimination by obtaining: positive results from samples with the analyte negative results from samples without the analyte Slide 27 PharmOut 2015

Detection limit The lowest amount of analyte in a sample that can be detected is the detection limit. Not necessarily quantified as an exact value. Slide 28 PharmOut 2015

Quantitation limit The quantitation limit is the lowest amount of analyte that can be quantitatively determined with acceptable precision and accuracy. The quantitation limit is typically required for impurities and/or degradation product determinations. Slide 29 PharmOut 2015

Linearity Ability to obtain results that are directly proportional to the concentration of an analyte in the sample. A minimum of 5 concentrations should be used to establish linearity. May demonstrate linearity directly on the drug substance (dilution of a standard stock solution). Slide 30 PharmOut 2015

Range determined by confirming that the procedure provides an acceptable degree of linearity, accuracy and precision. use amounts of analyte within or at the extremes of the specified range of the procedure being validated. Slide 31 PharmOut 2015

Range Consider the following minimum specified ranges: Assay for drug substance or finished product 80 120 percent of the test concentration Content uniformity 70 130 percent of the test concentration Dissolution testing +/- 20 percent over the specified range Slide 32 PharmOut 2015

Robustness ability to remain unaffected by small, deliberate variations in method parameters provides an indication of the reliability of the method during routine use usually only for method development phase; if not done then, it should be done during method validation Slide 33 PharmOut 2015

Robustness Examples of typical variations: Stability of solutions Temperature / humidity MP flow rate, ph, composition Different columns for chromatography tests (lots/suppliers) Slide 34 PharmOut 2015

Validation requirements for analytical assays: ICH Q2(R1) Slide 35 PharmOut 2015

System suitability testing (SST) based on the concept that the equipment, electronics, analytical operations and samples to be analysed constitute an integral system SST parameters for a particular procedure depend on the type of procedure being validated. Refer to Pharmacopoeias for more information. Reference: ICH Q2(R1) Slide 36 PharmOut 2015

Re-validation of methods What situations will require re-validation of an analytical test? Slide 38 PharmOut 2015

Re-validation of methods May be required in the following situations: Changes in the synthesis of the drug substance Finished product composition has changed Testing procedure has changed Slide 39 PharmOut 2015

Method validation report Complete a validation report once validation protocol has been executed. The report should have enough detail to be reviewed without the need for raw data. Must be linked to the protocol (reference protocol number). Report should have clear conclusions supported by data. Deviations should be reported and explained. Slide 45 PharmOut 2015

Sample verification report Slide 46 PharmOut 2015

Summary The aim of validating an analytical procedure is to demonstrate that it is fit for purpose. The objective of the analytical procedure must be understood to determine which of the validation characteristics need to be evaluated. Method validation must be documented, reviewed and approved. Slide 47 PharmOut 2015

Thank you for your time. Questions? Debbie Parker Senior Consultant Debbie.parker@pharmout.net www.pharmout.net Slide 48 PharmOut 2015